Search

Your search keyword '"Chen, Meilan"' showing total 316 results
Start Over Author "Chen, Meilan"
316 results on '"Chen, Meilan"'

9. Application of the combined problem-based learning and case-based learning teaching in urinalysis course of diagnostics

Author

Guo, Qunying, primary, Ke, Weijian, additional, Zeng, Zixia, additional, Liu, Juan, additional, Chen, Meilan, additional, Qiu, Qian, additional, Xue, Ruicong, additional, Su, Chang, additional, Tan, Niandi, additional, Wang, Haiyan, additional, Li, Bin, additional, Li, Junxun, additional, Yang, Daya, additional, Zhou, Yanbin, additional, Xiao, Haipeng, additional, and Chen, Weiying, additional

Published
2024
Full Text
View/download PDF

13. Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study

Author

Li Xiaozhe MD, Chen Meilan MD, Huang Beihui MD, Liu Junru MD, Gu Jingli MD, Kuang Lifen MD, and Li Juan MD

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Purpose: Pegylated liposomal doxorubicin (PLD) is highly effective for treating multiple myeloma (MM). Hand-foot syndrome (HFS) is a dose-limiting adverse event of PLD that may reduce a patient’s quality of life or prevent certain patients from receiving PLD. Several researchers have discovered that pyridoxine, an activated form of vitamin B6, may prevent PLD-associated HFS. We designed a prospective randomized trial to examine whether prophylactic pyridoxine might prevent the incidence or delay the occurrence of PLD-induced HFS in patients with MM. Methods: Patients who met the trial’s eligibility requirements were randomized and then administered either pyridoxine 100 mg twice daily or no pyridoxine, in both cases accompanied by their PLD-containing chemotherapeutic agent. Follow-up of patients was performed until the completion of induction therapy, the development of HFS or disease progression. Results: Between January 1, 2017, and January 1, 2019, 105 patients were randomly assigned to the pyridoxine group (n = 52) or the no pyridoxine group (n = 53). In the pyridoxine and no pyridoxine groups, HFS developed after a median of 4 (range, 1-8 cycles) and 3 (range, 1-7 cycles) chemotherapeutic cycles, respectively. There were no grade 3 incidents recorded. Overall, 13.3% of patients experienced HFS. A 11 of 53 (20.8%) patients in the no pyridoxine group experienced HFS, compared to 3 of 52 (5.8%) patients in the pyridoxine group ( P = .042); there was no difference in HFS grades ( P = .725). Conclusions: The findings of benefit from prophylactic pyridoxine in this open-label trial have suggested its promise as a treatment for reducing HFS in MM patients. Further research with a placebo-controlled design is recommended. Clinical Trial Registration: ChiCTR2100050294.

Published
2022
Full Text
View/download PDF

16. Development, Validation, and Application of the Turbulent Combustion Model for 3D CFD Code CYCAS

Author

Li Yabing, Chen Peng, Lin Chubin, and Chen Meilan

Subjects
turbulent combustion, hydrogen risk, containment safety, slow deflagration, CFD, General Works
Abstract

The CYCAS code is a 3D CFD code developed independently by the China Nuclear Power Research Institute, aiming at hydrogen safety analysis in containments. In order to equip the CYCAS code with the capability of combustion analysis, a combustion model is screened and developed, and validated with two cases from International Standard Problems. Then a combustion analysis is conducted with a containment to demonstrate the capability of CYCAS to evaluate the pressure and thermal load of combustion. Firstly, the mature and widely-used combustion model, i.e., the Burning Velocity Model (BVM) with Zimont correlation is developed for the CYCAS code in this study. Thereafter, the lamiar flame speed correlation for CYCAS is screened based on the containment atmospheric condition during the accidents. Then, two cases from the THAI facility are calculated to validate the model. The results show that the combustion model in CYCAS manages to have reasonable prediction on the slow deflagration for the gas mixture both with and without steam. Finally, a containment combustion analysis is conducted with the initial hydrogen distribution calculated from a postulated accident. The analysis shows that the CYCAS manages to calculate the pressure and thermal load of the combustion to evaluate the influence of the combustion on the containment integrity and equipment survivability.

Published
2022
Full Text
View/download PDF

25. Genome-Wide Characterization and Expression of the Hsf Gene Family in Salvia miltiorrhiza (Danshen) and the Potential Thermotolerance of SmHsf1 and SmHsf7 in Yeast

Author

Qu, Renjun, primary, Wang, Shiwei, additional, Wang, Xinxin, additional, Peng, Jiaming, additional, Guo, Juan, additional, Cui, Guanghong, additional, Chen, Meilan, additional, Mu, Jing, additional, Lai, Changjiangsheng, additional, Huang, Luqi, additional, Wang, Sheng, additional, and Shen, Ye, additional

Published
2023
Full Text
View/download PDF

28. Chloroplast genome of ​Thesium chinense:The insight into phylogeny of Santalaceae

Author

Zhao, Zhenyu, Li, Hongxiu, Chen, Meilan, Cheng, Meng, Gustavo Pedro, Cadiz Quispe, Zhou, Xiuteng, and Huang, Luqi

Abstract

Thesium chinenseis an important and commonly used traditional Chinese medicine. The aim of this study is to obtain more bioinformatics from Thesium chinenseand to conduct a more comprehensive and in-depth analysis of Santalaceae's phylogeny. This study sequenced the chloroplast genome of Thesium chinenseand performed bioinformatics analysis on its key genes to reconstruct the Santalaceae phylogenetic tree. The genes of traditional Chinese medicine often affect the generation and accumulation of metabolic products. The different genes in the chloroplast genome of Thesium chinensehave different biological characteristics. The phylogenetic system of Santalaceae and its related families differs significantly from classical classification. This study has laid a solid foundation for the better application and identification of Thesium chinense.

Published
2023
Full Text
View/download PDF

34. Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study

Author

Juan Li, Xiaozhe Li, Chen Meilan, Huang Beihui, Liu Junru, Gu Jingli, and Kuang Lifen

Subjects
Complementary and alternative medicine, Oncology, Doxorubicin, Quality of Life, Humans, Pyridoxine, Hand-Foot Syndrome, Prospective Studies, Multiple Myeloma
Abstract

Purpose: Pegylated liposomal doxorubicin (PLD) is highly effective for treating multiple myeloma (MM). Hand-foot syndrome (HFS) is a dose-limiting adverse event of PLD that may reduce a patient’s quality of life or prevent certain patients from receiving PLD. Several researchers have discovered that pyridoxine, an activated form of vitamin B6, may prevent PLD-associated HFS. We designed a prospective randomized trial to examine whether prophylactic pyridoxine might prevent the incidence or delay the occurrence of PLD-induced HFS in patients with MM. Methods: Patients who met the trial’s eligibility requirements were randomized and then administered either pyridoxine 100 mg twice daily or no pyridoxine, in both cases accompanied by their PLD-containing chemotherapeutic agent. Follow-up of patients was performed until the completion of induction therapy, the development of HFS or disease progression. Results: Between January 1, 2017, and January 1, 2019, 105 patients were randomly assigned to the pyridoxine group (n = 52) or the no pyridoxine group (n = 53). In the pyridoxine and no pyridoxine groups, HFS developed after a median of 4 (range, 1-8 cycles) and 3 (range, 1-7 cycles) chemotherapeutic cycles, respectively. There were no grade 3 incidents recorded. Overall, 13.3% of patients experienced HFS. A 11 of 53 (20.8%) patients in the no pyridoxine group experienced HFS, compared to 3 of 52 (5.8%) patients in the pyridoxine group ( P = .042); there was no difference in HFS grades ( P = .725). Conclusions: The findings of benefit from prophylactic pyridoxine in this open-label trial have suggested its promise as a treatment for reducing HFS in MM patients. Further research with a placebo-controlled design is recommended. Clinical Trial Registration: ChiCTR2100050294.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results